Life Molecular Imaging Collaboration Agreement

15 April 2024, IXICO plc (AIM: IXI), London, UK, the medical imaging advanced analytics company delivering intelligent insights in neuroscience, today provides information on its agreement with Life Molecular Imaging (LMI) for the supply of LMI's Neuraceq® Amyloid PET tracer (Florbetaben-18F) for use in pharma-sponsored clinical trials. Neuraceq® is a diagnostic agent that improves early detection and characterization of chronic and life-threatening diseases such as Alzheimer's, leading to better therapeutic outcomes and improved quality of life.

As a result of its agreement with LMI, IXICO is able to further extend its service offering to providing Neuraceq® PET tracer supply to complement IXICO's well-established PET imaging services and image data analytics.  LMI's provision of tracer supply to imaging centres together with IXICO's oversight of imaging will minimise the operational burden to trial sponsors and will improve patient experience, ultimately driving study eligibility and efficacy endpoint delivery. 


Andrew Stephens, Chief Medical Officer of Life Molecular Imaging, commented:

''We are pleased to be partnering with IXICO to further strengthen access to Neuraceq® to clinical trials. We hope that our partnership will offer Sponsors an additional streamlined route to tracer supply.''

Giulio Cerroni, Chief Executive Officer of IXICO, commented:

''IXICO is committed to the continuous development of our suite of AI enabled analytics and reader services for innovative new PET tracers and so we are delighted to be partnering with LMI to improve access and supply to LMI's Neuraceq. We anticipate that the extension of this Neuraceq tracer co-ordination service from IXICO will be very well received by our global biopharmaceutical Sponsors."

About IXICO | Advanced Analytics | Intelligent Insights.

IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis. 

IXICO has developed and deployed breakthrough data analytics, at scale, through its remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.

About Life Molecular Imaging (LMI)

Life Molecular Imaging (LMI) is an international pharma company dedicated to developing and offering novel cutting-edge PET radiopharmaceuticals for imaging of neurodegenerative and cardiovascular diseases. The organization strives to be a leader in the molecular imaging field. Our mission is to pioneer innovative PET products that improve early detection and characterization of chronic and life-threatening diseases, leading to better therapeutic outcomes and improved quality of life. By advancing novel PET radiopharmaceuticals for molecular imaging, LMI is focusing on a key field of modern medicine. LMI is an affiliate of Life Healthcare Group - an international people-centred, diversified healthcare organization with four decades of experience in the South African private healthcare sector.

More information about Life Molecular Imaging (LMI) at

About Life Healthcare Group

About Neuraceq® (florbetaben 18F)

For further information please contact:

Giulio Cerroni, Chief Executive Officer

Grant Nash, Chief Financial Officer

+44 (0)20 3763 7499


Date: 15/04/2024